Edition:
Deutschland

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

18.03USD
1 Jul 2020
Change (% chg)

$0.04 (+0.22%)
Prev Close
$17.99
Open
$17.99
Day's High
$18.07
Day's Low
$17.99
Volume
3,370,016
Avg. Vol
739,315
52-wk High
$31.72
52-wk Low
$5.31

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Buy/Sell

No Data Available
Sell Hold Buy

Overall

Beta: 2.30
Market Cap(Mil.): $1,415.06
Shares Outstanding(Mil.): 78.48
Dividend: --
Yield (%): --

UPDATE 2-Activist investor Elliott pushes Alexion Pharma to sell itself

May 12 Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

Elliott again pushes Alexion Pharma to explore a sale

May 12 Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.

BRIEF-Elliott Advisors Sends Letter To Alexion Pharmaceuticals

* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE

BRIEF-Portola Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Portola Pharmaceuticals Cancels Q1 Results Webcast And Conference Call Following Agreement To Be Acquired By Alexion

* PORTOLA PHARMACEUTICALS CANCELS FIRST QUARTER 2020 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL FOLLOWING AGREEMENT TO BE ACQUIRED BY ALEXION Source text for Eikon: Further company coverage:

Deals of the day-Mergers and acquisitions

May 5 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Alexion bets on Portola's bleeding antidote with $1.41 billion deal

Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.

UPDATE 3-Alexion bets on Portola's bleeding antidote with $1.41 bln deal

May 5 Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.

CORRECTED-UPDATE 1-Alexion to buy Portola Pharmaceuticals in $1.41 bln deal

May 5 Drugmaker Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values its smaller rival at $1.41 billion to gain access to a treatment for reversing the effects of blood thinners.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.25%
Rohstoffe -0.11%
Industrie -0.13%
Konjunktur abhängige Waren & Dienstleistungen -0.07%
Konjunktur unabhängige Waren & Dienstleistungen -0.19%
Finanzindustrie -0.07%
Pharma -0.01%
Technologie -0.34%
Telekommunikation -0.08%